Calliditas Therapeutics IPO Presentation Deck
Autoimmune Hepatitis
The disease
Autoimmune Hepatitis (AIH) is a rare, orphan, chronic
inflammation of the liver¹
Leads at variable rates to cirrhosis with complications such as
portal hypertension, liver failure and liver cancer
Typical symptoms are fatigue, abdominal discomfort, jaundice,
enlarged liver, skin rashes, joint pains and, in women, loss of
menstruation
Estimated prevalence²
50-90% will relapse following cessation of treatment
We estimate the intolerance to be 13-15% of the total population
50,000-80,000
Standard of care³
Currently no products approved in the U.S.; standard of care includes immunosuppression with systemic
corticosteroids (prednisone) alone or in combination with azathioprine
Annual U.S.
incidence
0.1-1.9 per
100,000
Up to 80% of treated patients report steroid related side effects after 2 years and 15% discontinue due to drug-
related adverse events
calliditas
Source: 1) Feld et al, Hepatology 2005:42:53-62, Sahebjam and Vierling, Front Med. 2015 Jun (2) 187-219. 2) Sahebjam and Vierling, Front Med 2015; 9(2):187-219.3) Czaja, Expert Opin Drug Sal. 2008 7(3):319-33; Czaja, Liver Ins 2009-29(6):816-23; Manns et al,
Hepatology 2010;51(6):2193-213 (AASLD 2010 AIH Guideline).
June 2020
29View entire presentation